



5-4-07

CASE TX/4-32662A US-PCT

1625
1/8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1625

ALBERT ET AL.

Examiner: Sarah E Perlinger

APPLICATION NO: 10/529,776

FILED: MAY 5, 2005

FOR: PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

Novartis AG, a company organized under the laws of the Swiss Confederation, having a place of business at Lichtstrasse 35, Basel, Switzerland 4056, represents that it is the assignee and owner of the entire interest in the above-identified application by virtue of an assignment which is being transmitted for recordation in the United States Patent and Trademark Office concurrently herewith. A copy is attached hereto.

Novartis AG hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 USC §154-156 and §173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending **Application No. 10/472,653** filed April 8, 2002. Said Application No. 10/472,653 is also assigned to Novartis AG by virtue of an assignment which an assignment which was recorded in the United States Patent and Trademark Office on April 27, 2007 at Reel/Frame 019223/0426.

Novartis AG hereby agrees that any patent granted on the above-identified application shall be enforceable only for and during such period that it and any patent granted on Application No. 10/472,653 are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.


In making the above disclaimer, Novartis AG does not disclaim the terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term as defined in 35 USC §154-156 and §173 of any patent granted on Application No. 10/472,653, as shortened by any terminal disclaimer filed prior to the patent grant, in the

event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

A terminal disclaimer fee under 37 CFR §1.20(d) is included.

Signed this 3rd day of May, 2007 by the undersigned attorney of record.

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV971833276 US
Express Mail Label Number

MAY 3, 2007
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1625

ALBERT ET AL.

Examiner: Sarah E Perlinger

APPLICATION NO: 10/529,776

FILED: MAY 5, 2005

FOR: PIPERIDINE DERIVATIVES AS CCR5 INHIBITORS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER

Sir:

Enclosed herewith is a Terminal Disclaimer in the above-identified application.

The Commissioner is hereby authorized to charge the \$130 fee under 37 CFR §1.20(d) and any additional fees that may be required to Deposit Account No. 19-0134 in the name of Novartis. An additional copy of this paper is here enclosed.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909

Date: May 3, 2007

Thomas R. Savitsky
Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661